XNASLFMDP
Market cap220mUSD
Dec 24, Last price
22.05USD
1D
-0.23%
1Q
0.23%
Name
LifeMD Inc
Profile
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 152,547 28.15% | 119,034 28.16% | 92,876 149.04% | |||||||
Cost of revenue | 153,107 | 146,968 | 140,886 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (560) | (27,935) | (48,010) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 428 | 361 | 8 | |||||||
Tax Rate | ||||||||||
NOPAT | (988) | (28,296) | (48,018) | |||||||
Net income | (20,596) -54.25% | (45,021) -26.59% | (61,324) 1.32% | |||||||
Dividends | (3,106) | (3,106) | (871) | |||||||
Dividend yield | 1.11% | 5.17% | 0.83% | |||||||
Proceeds from repurchase of equity | 16,203 | 86,447 | ||||||||
BB yield | -5.76% | -82.71% | ||||||||
Debt | ||||||||||
Debt current | 1,534 | 3,553 | 671 | |||||||
Long-term debt | 18,679 | 1,904 | 2,965 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 131 | 1,023 | 100 | |||||||
Net debt | (12,934) | 1,499 | (37,693) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 8,820 | (22,935) | (33,085) | |||||||
CAPEX | (204) | (12,893) | (3,402) | |||||||
Cash from investing activities | (8,733) | (13,906) | (3,402) | |||||||
Cash from financing activities | 29,101 | (528) | 68,637 | |||||||
FCF | (17,013) | (11,355) | (51,194) | |||||||
Balance | ||||||||||
Cash | 33,147 | 3,959 | 41,328 | |||||||
Long term investments | ||||||||||
Excess cash | 25,519 | 36,684 | ||||||||
Stockholders' equity | (211,821) | (186,157) | (138,535) | |||||||
Invested Capital | 237,054 | 181,501 | 164,303 | |||||||
ROIC | ||||||||||
ROCE | 599.98% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 33,905 | 30,976 | 27,008 | |||||||
Price | 8.29 327.32% | 1.94 -49.87% | 3.87 -40.74% | |||||||
Market cap | 281,074 367.72% | 60,094 -42.50% | 104,521 12.13% | |||||||
EV | 270,200 | 65,683 | 69,907 | |||||||
EBITDA | 6,041 | (24,165) | (47,141) | |||||||
EV/EBITDA | 44.73 | |||||||||
Interest | 2,597 | 1,276 | 3,020 | |||||||
Interest/NOPBT |